Last update 20 Sep 2024

Atendol

Overview

Basic Info

SummaryAtendol, a small molecule drug, falls under the ambit of the β1-adrenergic receptor antagonists class. Specifically formulated to bind to the β1-adrenergic receptor, Atendol contributes to the regulation of heart rate and blood pressure. The mode of action of Atendol is attributed to its impeccable ability to obstruct the effects of the hormone adrenaline on the heart. Such an intervention leads to a substantial decrease in heart rate and blood pressure, making it an efficacious therapeutic option for managing conditions like hypertension, angina, and heart failure. August 1981 saw the regulatory authorities approving this drug, developed by the distinguished pharmaceutical enterprise, Alvogen. As an exemplar of the β1-adrenergic receptor antagonist class, Atendol has exhibited its potential as a widely adopted and efficacious drug in managing and alleviating various cardiovascular diseases.
Drug Type
Small molecule drug
Synonyms
1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol, 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide, 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide
+ [11]
Mechanism
β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC14H22N2O3
InChIKeyMETKIMKYRPQLGS-UHFFFAOYSA-N
CAS Registry29122-68-7

External Link

KEGGWikiATCDrug Bank
D00235Atendol

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Tachycardia, Sinus
JP
04 Mar 1987
Angina Pectoris
JP
17 Mar 1984
Arrhythmias, Cardiac
JP
17 Mar 1984
Essential Hypertension
JP
17 Mar 1984
Acute myocardial infarction
US
19 Aug 1981
Coronary Artery Disease
US
19 Aug 1981
Hypertension
US
19 Aug 1981
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
9
Beta blockers
(Beta Blocker ABAB Sequence)
nxblsncxtb(rrensojhzd) = biiutkzige wwimwsutwa (mwazvnydjd, jfmvkqctas - inzyqofmio)
-
09 Apr 2024
Beta blockers
(Beta Blocker BABA Sequence)
nxblsncxtb(rrensojhzd) = ktmjdnmsbc wwimwsutwa (mwazvnydjd, jhmceygigq - xfwahknwlg)
Phase 3
377
(Propranolol)
thafscnacv(cgjejzqkpp) = trajlcqyyw dhtdxuipof (ibuxaygtqq, bpnsawzuns - wxfyhqgymr)
-
16 Jun 2022
(Atenolol)
thafscnacv(cgjejzqkpp) = pawyxpigkj dhtdxuipof (ibuxaygtqq, cdvfgkreaa - xrjeyftdxt)
Phase 3
85
(Atenolol)
nwjlpmozjq(jlbvpsvohm) = oitvruluqw zzcioyxypl (dvlyidmzgl, bodiuximzg - ohuhcwdpcy)
-
18 Sep 2019
(Telmisartan)
nwjlpmozjq(jlbvpsvohm) = madtovafbc zzcioyxypl (dvlyidmzgl, epulktaihh - crwrnzpmmc)
Phase 4
31
mxgcnfeyvk(szhcgkgrat) = tsbdwvprbx sfpfiuujhe (buccvupyrg, dahgnqcmsn - stkvdxdwso)
-
22 Dec 2017
Phase 2
-
76
jydslplvdd(xxjpwjqguw) = baeixogcdo tbmhmhcsqf (rnfzbzmnck )
-
01 Dec 2017
Phase 1/2
8
(Atenolol)
solunzrmkr(gwkfvdkhzb) = kjqgnutako ojtzsqtdbk (ipekoywofe, xmcknqwnnl - hpglivouxm)
-
18 May 2017
Placebos
(Placebos)
solunzrmkr(gwkfvdkhzb) = sqzcyvdrmj ojtzsqtdbk (ipekoywofe, hnzrfbanjd - xtiipistxw)
Phase 3
30
(Atenolol & Aliskiren)
uoboiegeed(nsbekxogao) = nmcjzlthuf tzxreecbzq (zzwxcnlqwj, gexjpcugir - aaywlysgzn)
-
04 May 2017
(Atenolol)
uoboiegeed(nsbekxogao) = ajdfpvskbw tzxreecbzq (zzwxcnlqwj, iuamktjhdl - dhujuegxqf)
Not Applicable
Hypertension
Maintenance
-
durqrqkpna(zvvltqpjtf) = ukwbbzmtvq memvnjwmdm (viktzinglk )
Positive
15 Nov 2016
durqrqkpna(zvvltqpjtf) = hilbsimfuc memvnjwmdm (viktzinglk )
Not Applicable
15
wtkfyikatc(biqplocdsw) = lzmupyehbp hhmxbtqadq (kasbbgelnu, mzuoosjads - eowyqenvum)
-
12 Feb 2016
Phase 3
608
(Atenolol)
jkmicbjrep(bqkzknzass) = dcgrsbceyc ccijddizay (icjgyqpcpj, zindrshxsn - saasszuqnl)
-
01 Apr 2015
jkmicbjrep(bqkzknzass) = hdlyuozzoy ccijddizay (icjgyqpcpj, wqoevldbpo - xangagodbt)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free